Pentostatin

喷司他丁

Report date: 2022/12/07 17:52:12
NME

Base Information

Drug NamePentostatin
Drug Alias NameCovidarabine喷妥司丁pentostatina喷司他汀pentostatine +[18] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionAdenosine deaminase inhibitors
TargetsAdenosine deaminase
Therapy Area/IndicationsGraft vs Host DiseaseMyeloproliferative DisordersMyelodysplastic Syndromes +[11] 
Global Approved IndicationsLymphoma, T-Cell, CutaneousLeukemia, Hairy Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1991/10/11
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesHospira IncHangzhou Huadong Medicine Group Biotechnology Institute Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesHospiraYale UniversityNational Cancer Institute +[7] 
Active IndicationsLymphoma, T-Cell, CutaneousLeukemia, Hairy Cell
Inactive IndicationsGraft vs Host DiseaseMyeloproliferative DisordersMyelodysplastic Syndromes +[9] 

Other Information

ATC CodeL01XX08
Related LinksWikipediaDrugBankKEGG